What question did this study set out to answer?

To evaluate the clinical impact of escalating tamsulosin dosage from 0.2 mg to 0.4 mg in patients with benign prostatic hyperplasia who responded inadequately to the lower dose.

January 1, 2026Korean journal of urologyOpen Access

The efficacy of tamsulosin 0.4 mg when tamsulosin 0.2 mg is insufficient for benign prostatic hyperplasia in Korean patients

View Full Paper

Ask AI

Bookmark

To evaluate the clinical impact of escalating tamsulosin dosage from 0.2 mg to 0.4 mg in patients with benign prostatic hyperplasia who responded inadequately to the lower dose.
Retrospective review of 57 patients treated at Seoul National University Bundang Hospital in 2022.
Assessed uroflowmetry parameters, International Prostate Symptom Score (IPSS), and postvoid residual volume (PVR) before and after dose escalation.
Performed subgroup analyses based on age, prostate volume, and concomitant 5-alpha-reductase inhibitor use.
Mean maximum urinary flow rate increased significantly from 14.4 mL/s to 17.7 mL/s following dose escalation (p < 0.001), showing consistent improvements across all subgroups.
Overall International Prostate Symptom Score and postvoid residual volume demonstrated no statistically significant change across the total cohort.
Postvoid residual volume decreased significantly in the subgroup of patients with prostate volumes exceeding 50 mL.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective review finds improved urinary flow following tamsulosin dose escalation in men with benign prostatic hyperplasia, highlighting clinical value for inadequate lower-dose responses.

Cite This Study

Chung et al. (2026) studied this question.

synapsesocial.com/papers/6a776ae6e29fd788c9f74716 https://doi.org/10.4111/icu.20250569

View Full Paper

Ask AI

Bookmark

Implication

Retrospective review finds improved urinary flow following tamsulosin dose escalation in men with benign prostatic hyperplasia, highlighting clinical value for inadequate lower-dose responses.

The efficacy of tamsulosin 0.4 mg when tamsulosin 0.2 mg is insufficient for benign prostatic hyperplasia in Korean patients

Key Points

Discussion

Implication

Cite This Study

The efficacy of tamsulosin 0.4 mg when tamsulosin 0.2 mg is insufficient for benign prostatic hyperplasia in Korean patients

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider